XML 17 R8.htm IDEA: XBRL DOCUMENT

ACQUISITION OF DECAHEDRON, LTD.

3 Months Ended

Mar. 31, 2017

On February 10, 2017, the Company completed the acquisition Decahedron pursuant to the Decahedron SPA acquiring 100% of the outstanding shares of Decahedron, a United Kingdom Company, a pharmaceuticals wholesaler which specializes in imports and exports of branded and generic pharmaceutical products within the EEA and around the world. At closing, the Company acquired 100% of Decahedron’s outstanding shares in exchange for 1,700,000 shares of Cosmos common stock valued at $1,479,000 (the "Acquisition").

The Company recognized the Decahedron assets acquired and liabilities assumed based upon the fair value of such assets and liabilities measured as of the date of acquisition. The aggregate purchase price for Decahedron has been allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the license held by Decahedron for the wholesale of pharmaceuticals in the United Kingdome and Europe, the remainder has been allocated to goodwill, none of which is tax deductible.

During the quarter ended March 31, 2017, we recorded an adjustment of $28,002 primarily related to other assets and an adjustment of the accounts payable associated with the Decahedron acquisition. We finalized our allocation of purchase price during the quarter ended March 31, 2017. The final unaudited allocation of purchase price as of March 31, 2017, is as follows:

	Preliminary
	Allocation as of
	February10, 2017			Allocation Adjustments			Final Allocation
Current assets	$	6,537		$	-		$	6,537
Intangible assets		50,000			-			50,000
Other assets		305,400			(216,562	)		88,838
Total assets acquired		361,937			(216,562	)		145,375
Liabilities assumed:
Debt		804,819			(188,560	)		616,259
Total liabilities assumed		804,819			(188,560	)		616,259
Net assets acquired		(442,882	)		(28,002	)		(470,884	)
Consideration:
Value of Common Stock Issued at Acquisition		1,479,000			-			1,479,000
Goodwill	$	1,921,882		$	28,002		$	1,949,884

The components of the acquired intangible assets were as follows (in thousands):

Amount

Useful

Life

(Years)

Licenses (a)

50,000

(a)

U.K Pharmaceutical Wholesale Distribution License

Unaudited Supplemental Pro Forma Data

The pro forma statements of operations data for the three months ended March 31, 2017, below, give effect to the Decahedron Acquisition, described above, as if it had occurred at January 1, 2017. These amounts have been calculated after applying our accounting policies and adjusting the results of Decahedron intangible amortization that would have been charged assuming the fair value adjustments had been applied and incurred since January 1, 2017. This pro forma data is presented for informational purposes only and does not purport to be indicative of our future results of operations.

Revenue of $426,798 and net loss of $33,977 since the acquisition date are included in the consolidated statement of operations and comprehensive income (loss) for three months ended March 31, 2017.

Unaudited proforma results of operations for the three months ended March 31, 2017 and 2016 as though the Company acquired Decahedron on the first of each fiscal year are set forth below.

	Three months ended March 31,
	2017			2016
Revenues	$	4,309,363		$	1,636,740
Cost of revenues		3,951,657			1,542,171
Gross profit		357,706			94,569

Operating expenses		2,376,517			175,780
Operating loss		(2,018,811	)		(81,211	)

Other income (expense)		(101,567	)		(268,098	)

Net Loss	$	(2,120,378	)	$	(349,309	)

The purchase price exceeded the estimated fair value of the net assets acquired by $1,949,884 which was recorded as Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from Decahedron and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. At the conclusion of the acquisition, goodwill was reviewed for impairment and it was determined that indicators of impairment existed.

As of March 31, 2017, after our assessment of the totality of the events that could impair goodwill, it was the Company’s conclusion “it is not more likely than not” that the Goodwill was impaired. Therefore, the Company was not required to conduct a two-step quantitative goodwill impairment test. No events have occurred after March 31, 2017 that would affect the Company’s conclusion as of the March 31, 2017 assessment date. As a result of the Company’s assessment, 100% of the goodwill of $1,949,884 was recorded as an impairment of goodwill.